Clinical trials: Effect of Drugs
Solid Tumor, Lymphoma, Malignant
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
The purpose of this study is to assess the effect of enzastaurin (LY317615), on a protein (enzyme CYP2C9) which is involved in the metabolic pathway of warfarin in participants with solid tumors or lymphomas.
- Trial name
- NCT01388335
- Testing
- warfarin, enzastaurin
- Where
- 7 sites in France
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Nonhematologic Malignancies, Lymphoma
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
This is an open-label, multicenter, sequential, 5-arm, phase 1 study of oral IXAZOMIB designed to assess drug-drug interaction with ketoconazole (Arm 1), the relative bioavailability of 2 capsule formulations of IXAZOMIB (Arm 2)…
- Trial name
- NCT01454076
- Testing
- Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
HIV Infections
Drug Interaction Study With Proton Pump Inhibitor
The purpose of this clinical research study is to assess the effect of omeprazole at 20 mg on the pharmacokinetics of atazanavir administered as atazanavir with ritonavir relative to atazanavir or atazanavir/ritonavir in the…
- Trial name
- NCT00357240
- Testing
- Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Drug Drug Interaction
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects
- Trial name
- NCT05574374
- Testing
- DWP14012, DWC202202, DWC202203
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Asthma
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast…
- Trial name
- NCT00092989
- Testing
- montelukast sodium
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Pharmacokinetics, Cytochrome P-450 CYP2D6
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects.
- Conditions
- Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
- Trial name
- NCT01188668
- Testing
- Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Achondroplasia
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
- Trial name
- NCT03583697
- Testing
- BMN 111
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 75 people
- Sponsor
- BioMarin Pharmaceutical
Healthy Volunteer
GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir
The purpose of this study is to compare the amount of GSK1349572 (study drug) in the blood when given with and without atazanavir/ritonavir or atazanavir and to compare the blood levels of atazanavir when given with GSK1349572 to…
- Trial name
- NCT00883935
- Testing
- GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psychological Effects of Study Drug
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)
The goal of this clinical trial is to study MDMA-assisted therapy in healthy volunteers and provide training of therapists. The main question it aims to answer is: Does MDMA-assisted therapy result in personal and professional…
- Trial name
- NCT04073433
- Testing
- Midomafetamine HCl, Therapy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Chronic Hepatitis C Infection
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the study drugs when administered…
- Trial name
- NCT01813552
- Testing
- Samatasvir, Omeprazole, Ritonavir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
- Trial name
- NCT02382640
- Testing
- Febuxostat XR, Maalox Advance Regular Strength liquid
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
This study is not being conducted in the United States. The purpose of this study is to assess the effect of vildagliptin, an unapproved drug, on various measures of pancreatic islet function in people with type 2 diabetes who…
- Trial name
- NCT00260156
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Gout, Hyperuricemia
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy…
- Trial name
- NCT03927677
- Testing
- Xanthine Oxidase Inhibitor
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Healthy Volunteers
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9…
- Trial name
- NCT05932277
- Testing
- BMS-986419, Caffeine, Bupropion
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Participant
A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.
The purpose of this study is to learn if a medicine called itraconazole changes how the body processes the study medicine (PF-08642534) in healthy adults.
- Trial name
- NCT07575945
- Testing
- PF-08642534, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gout, Food-drug Interaction
Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects
This is a single center, open-label, single-dose, 2-way randomized crossover design in which 12 healthy subjects will be randomized to 1 of 2 treatment sequences (AB or BA).
- Trial name
- NCT04303039
- Testing
- ABP-671
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd
Healthy Participants
Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1).
- Trial name
- NCT06205381
- Testing
- AV078, Itraconazole, Midazolam
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Aeovian Pharmaceuticals, Inc.
ER-Positive HER2-Negative Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in…
- Trial name
- SERENA-6 (NCT04964934)
- Testing
- AZD9833, Anastrozole, Letrozole
- Where
- 264 sites in United States, Australia and 21 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.